BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends

SG&A Expense Trends: BioMarin vs. Geron

In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and Geron Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. BioMarin's SG&A expenses have surged by over 200% from 2014 to 2023, reflecting its aggressive growth strategy and expansion efforts. In contrast, Geron Corporation's expenses have increased by approximately 300%, albeit from a much smaller base, indicating a more conservative yet steady approach.

Key Insights

• BioMarin's Growth: By 2023, BioMarin's SG&A expenses reached nearly $937 million, highlighting its significant market presence.
• Geron's Steady Rise: Geron's expenses, while smaller, have shown a consistent upward trend, reaching about $69 million in 2023.
  This data underscores the differing strategies of these two biotech firms, offering valuable insights for investors and industry analysts.